secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aspire Biopharma Holdings, Inc. (ASBP)
CIK:        0001847345
Form:       8-K
Filed at:   2026-04-16T23:59:59+00:00
Accession:  0001493152-26-017054
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Aspire Biopharma shareholders approve reverse stock split and authorized share increase
--------------------------------------------------------------------------------

- Reverse stock split ratio range 1:5 to 1:500 approved: 2,096,356 for, 582,185 against, 12,852 abstain.
- Authorized common stock increase from 490M to 700M shares passed: 1,925,368 for, 524,501 against, 7,403 abstain.
- Series A Preferred issuance for conversion shares and floor price approved: 1,466,141 for, 203,756 against, 8,652 abstain, 1,012,844 broker non-votes.
- ELOC Agreement share issuance approved: 1,469,985 for, 203,926 against, 4,638 abstain, 1,012,844 broker non-votes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1847345/000149315226017054/0001493152-26-017054-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1847345/000149315226017054/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-017054

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer